TG 1050

Drug Profile

TG 1050

Alternative Names: TG-1050

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Transgene
  • Developer Transgene; Transgene - Tasly Pharmaceutics Group (JV)
  • Class Hepatitis B vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 16 Nov 2016 Pharmacodynamics data from a preclinical trial in Hepatitis B presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 14 Nov 2016 Preclinical data presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 01 Oct 2015 Phase-I clinical trials in Hepatitis B (Treatment-experienced) in Germany, Canada, France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top